Date:5/17/2010

-- 1,372 Gain on sale of assets (15,082) (11,652) Rental expense borne by a related party 81,749 81,626 (Increase) decrease in assets: Accounts receivable, trade - related parties 4,933,543 (1,493,130) Other receivables 93,577 (17,415) Other receivables - related parties (1,200,159) (2,567,169) Inventories 304,560 1,398,175 Employee advances 13,935 (76,407) Prepaid expense 64,017 (589,907) Increase (decrease) in liabilities: Accounts payable (819,926) (567,056) Advances from customers - related parties 4,034,448 1,364,661 Wages and benefits payable (416,798) (393,303) Other taxes payable 550,140 (270,424) Other payables 19,487 (565,726) Other payables - related parties 1,079,414 106,916 Net cash provided by operating activities 13,029,773 5,857,746 CASH FLOWS FROM INVESTING ACTIVITIES: Investment in Life Resources 3,000,000 -- Proceeds from disposal of a subsidiary 700,000 -- Construction deposits (562,642) (1,163,628) Contractor deposits -- 48,930 Addition to construction in progress (9,112,590) (4,483,010) Equipment deposits (1,558,192) -- Proceeds from sales of proper
'/>"/>

SOURCE Tiens Biotech Group (USA), Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
5. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
6. Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference
7. Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
8. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
11. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.